Screener
Iovance Biotherapeutics, Inc. IOVA Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Net Loss Per Share of Common Stock, Basic and Diluted | $(0.11) | $(0.33) | $(0.29) | $(0.69) |
| Weighted Average Shares of Common Stock Outstanding, Basic and Diluted | 450,189 | 334,511 | 434,437 | 328,721 |
| * Non-cash stock-based compensation included in cost of sales and operating expenses | ||||
| Cost of sales | $1,536 | $2,149 | $2,555 | $4,569 |
| Research and development | 5,078 | 6,359 | 10,195 | 16,276 |
| Selling, general, and administrative | 5,119 | 6,435 | 10,252 | 17,013 |
| $11,733 | $14,943 | $23,002 | $37,858 | |
| ** Excludes depreciation and amortization |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s stock-based comp?
- Iovance Biotherapeutics, Inc. (IOVA) reported stock-based comp of $11.73M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s stock-based comp changed year-over-year?
- Iovance Biotherapeutics, Inc.'s stock-based comp decreased by 21.5% year-over-year, from $14.94M to $11.73M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s stock-based comp has grown at a -3.1% compound annual growth rate (CAGR), from $69.77M to $61.58M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Iovance Biotherapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude